secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001655759-23-000075
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q2 net loss $66.6M; vepdegestrant Phase 3 trials continue; ARV-766 shows 42% PSA50
--------------------------------------------------------------------------------

- Net loss $66.6M vs $70.0M YoY; revenue $54.5M (up from $33.8M) from collaboration agreements.
- Cash & securities $1,044.3M; expected to fund operations into 2026.
- VERITAC-2 (2L) and VERITAC-3 (1L) Phase 3 trials of vepdegestrant enrolling; first Phase 3 data expected 2H 2024.
- ARV-766 interim data: 42% PSA50 in AR LBD-mutant mCRPC patients; well-tolerated.
- John Houston named Chairperson; Sunil Agarwal appointed to Board; cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000075/0001655759-23-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000075/arvn-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001655759-23-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer